Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2021

View Archived Issues

CVL-231 safe in healthy volunteers; evaluation in schizophrenia patients ongoing

Studies reveal activity, mechanism of TAM kinase inhibitor PF-5807

Phase III study finds Xywav improves excessive daytime sleepiness

Observational study confirms good tolerability and efficacy of Intratect

Second pivotal study of IDP-126 achieves all coprimary endpoints with statistical significance

First patient dosed in investigator-initiated study of rigosertib in RDEB-associated SCC

Monopteros initiates phase I/Ib study of MPT-0118 in solid tumors

Phase III JUPITER-06 study of toripalimab plus chemotherapy meets primary endpoints

Medshine Discovery divulges PD-1/PD-L1 interaction inhibitors

Chinese investigators disclose HGFR and/or SRC and/or CSF1R inhibitors

Roche presents HBsAg secretion inhibitors

Alladapt initiates phase I/II Harmony Study of ADP-101

Shanghai Litedd identifies new ROR-gammaT agonists

Tolremo Therapeutics describes new DYRK1B inhibitors

Phase II trial of selective oral DHODH modulator vidofludimus in RRMS

FDA grants accelerated approval to Jemperli for dMMR endometrial cancer

ProtoKinetix resumes phase I trials of PKX-001-treated islet cells in patients with type 1 diabetes

ICAM-1 orchestrates radiotherapy abscopal effect

Discovery of JBI-1527, small molecule inhibitor of PD-L1/PD-1 interaction

OR-2805: a novel antibody targeting CD163 for the treatment of lung cancers

Zenith agrees with Astellas to study ZEN-3694 with enzalutamide in metastatic CRPC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...